...Novartis also has a NASH deal with Allergan plc (NYSE:AGN) to evaluate tropifexor plus Allergan's cenicriviroc... ...NR1H4) - Farnesoid X receptor; GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor
Mary Romeo, Staff Writer
cenicriviroc (tbr-652, TAK-652)
GS-0976...
...are Ocaliva obeticholic acid from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), selonsertib from Gilead Sciences Inc. (NASDAQ:GILD), cenicriviroc... ...treat primary biliary cirrhosis (PBC); selonsertib is an apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor; cenicriviroc... ...measures (see "New Endpoints in NASH" ). Comments are due Feb. 4, 2019.
Emily Cukier
cenicriviroc (tbr-652, TAK-652)
elafibranor...
...liver fibrosis. Last year, Novartis partnered with Allergan plc (NYSE:AGN) to evaluate tropifexor plus Allergan's cenicriviroc... ...is in the Phase II TANDEM trial to treat NASH and liver fibrosis. Allergan acquired cenicriviroc...